Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06590857 · ClinicalTrials.gov registry record · Phase 1

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

A Phase 1 study of Metastatic Breast Cancer and HER2-Negative Breast Cancer, sponsored by RayzeBio.

Active
Registry status
Phase 1
Development phase
16
Enrollment target
20
Study locations

NCT06590857 is a Phase 1 study of Metastatic Breast Cancer and HER2-Negative Breast Cancer that is active but no longer recruiting, run by RayzeBio. The registered enrollment target is 16 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06590857, a Phase 1 study of Metastatic Breast Cancer and HER2-Negative Breast Cancer, is active but no longer recruiting, sponsored by RayzeBio.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
16 participants
Enrollment target
20
Study locations

Study Summary

Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.

Conditions Studied

Metastatic Breast Cancer HER2-Negative Breast Cancer Advanced Breast Cancer ER+ Breast Cancer

Interventions

  • DRUG RYZ101

Study Locations (20)

California

  • Research Facility - Irvine
  • Research Facility - San Diego
  • Research Facility - Santa Monica

New York

  • Research Facility - Buffalo
  • Research Facility - New York
  • Research Facility - New York

Pennsylvania

  • Research Facility - Philadelphia
  • Research Facility - Pittsburgh

Arizona

  • Research Facility - Phoenix

Colorado

  • Research Facility - Longmont

Florida

  • Research Facility - Jacksonville

Georgia

  • Research Facility - Atlanta

Indiana

  • Research Facility - Indianapolis

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2024-07-19
Est. Completion 2033-01
Phase Phase 1

Sponsor

RayzeBio

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06590857

The ClinicalTrials.gov registry entry for NCT06590857 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (92% lower). The listed sponsor is RayzeBio, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which RYZ101 is the first listed.

NCT06590857 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, New York, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06590857 about?

NCT06590857 is a clinical study titled "Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.". Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.

What is the current status of trial NCT06590857?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2024-07-19. Estimated completion is 2033-01.

What conditions does trial NCT06590857 study?

This clinical trial studies the following conditions: Metastatic Breast Cancer, HER2-Negative Breast Cancer, Advanced Breast Cancer, ER+ Breast Cancer.

What interventions are being tested in trial NCT06590857?

The interventions under investigation include: RYZ101 (DRUG).

Who is sponsoring clinical trial NCT06590857?

This trial is sponsored by RayzeBio, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06590857 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Breast Cancer

All registered trials for this condition

HER2-Negative Breast Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.